ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.
Phase I Study Aims To Determine Optimum Oncolytic Virus Dose for Recurrent Astrocytoma
Credit: DR P. MARAZZI/SCIENCE PHOTO LIBRARY/Getty Images Henry Ford Health researchers have announced the initiation of a Phase I clinical trial to determine maximum tolerated